Five Prime Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2001-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.fiveprime.com
Safety Study of FP-1039 To Treat Cancer
Phase 1
Completed
- Conditions
- Advanced Cancer
- Interventions
- Drug: FP-1039
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00687505
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸START (South Texas Accelerated Research Therapeutics), San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath